Works matching AU Fukuoka, Masahiro

Results: 112
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.

    Published in:
    Japanese Journal of Clinical Oncology, 2025, v. 55, n. 3, p. 228, doi. 10.1093/jjco/hyae167
    By:
    • Uryu, Kiyoaki;
    • Imamura, Yoshinori;
    • Shimoyama, Rai;
    • Mase, Takahiro;
    • Fujimura, Yoshiaki;
    • Hayashi, Maki;
    • Ohtaki, Megu;
    • Otani, Keiko;
    • Hibino, Makoto;
    • Horiuchi, Shigeto;
    • Fukui, Tomoya;
    • Fukai, Ryuta;
    • Chihara, Yusuke;
    • Iwase, Akihiko;
    • Yamada, Noriko;
    • Tamura, Yukihiro;
    • Harada, Hiromasa;
    • Tsuya, Asuka;
    • Okabe, Takafumi;
    • Fukuoka, Masahiro
    Publication type:
    Article
    12

    Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).

    Published in:
    Japanese Journal of Clinical Oncology, 2024, v. 54, n. 3, p. 319, doi. 10.1093/jjco/hyad162
    By:
    • Uryu, Kiyoaki;
    • Imamura, Yoshinori;
    • Shimoyama, Rai;
    • Mase, Takahiro;
    • Fujimura, Yoshiaki;
    • Hayashi, Maki;
    • Ohtaki, Megu;
    • Otani, Keiko;
    • Hibino, Makoto;
    • Horiuchi, Shigeto;
    • Fukui, Tomoya;
    • Fukai, Ryuta;
    • Chihara, Yusuke;
    • Iwase, Akihiko;
    • Yamada, Noriko;
    • Tamura, Yukihiro;
    • Harada, Hiromasa;
    • Shinozaki, Nobuaki;
    • Tsuya, Asuka;
    • Fukuoka, Masahiro
    Publication type:
    Article
    13
    14
    15
    16
    17
    18

    Catheter detachment.

    Published in:
    Oxford Medical Case Reports, 2015, v. 2015, n. 5, p. 292, doi. 10.1093/omcr/omv038
    By:
    • Takayo Ota;
    • Hiroshi Tsukuda;
    • Masahiro Tokunaga;
    • Norifumi Nishida;
    • Yoshikazu Hasegawa;
    • Tomohiro Suzumura;
    • Masahiro Fukuoka
    Publication type:
    Article
    19

    Proteomic Biomarkers for Acute Interstitial Lung Disease in Gefitinib-Treated Japanese Lung Cancer Patients.

    Published in:
    PLoS ONE, 2011, v. 6, n. 7, p. 1, doi. 10.1371/journal.pone.0022062
    By:
    • Nyberg, Fredrik;
    • Ogiwara, Atsushi;
    • Harbron, Chris G.;
    • Kawakami, Takao;
    • Nagasaka, Keiko;
    • Takami, Sachiko;
    • Wada, Kazuya;
    • Tu, Hsiao-Kun;
    • Otsuji, Makiko;
    • Kyono, Yutaka;
    • Dobashi, Tae;
    • Komatsu, Yasuhiko;
    • Kihara, Makoto;
    • Akimoto, Shingo;
    • Peers, Ian S.;
    • South, Marie C.;
    • Higenbottam, Tim;
    • Fukuoka, Masahiro;
    • Nakata, Koichiro;
    • Ohe, Yuichiro
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    26

    ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer.

    Published in:
    Cancer Science, 2018, v. 109, n. 8, p. 2532, doi. 10.1111/cas.13651
    By:
    • Azuma, Koichi;
    • Nishio, Makoto;
    • Hayashi, Hidetoshi;
    • Kiura, Katsuyuki;
    • Satouchi, Miyako;
    • Sugawara, Shunichi;
    • Hida, Toyoaki;
    • Iwamoto, Yasuo;
    • Inoue, Akira;
    • Takeda, Koji;
    • Ikeda, Satoshi;
    • Nakagawa, Tomoki;
    • Takeda, Kentaro;
    • Asahina, Seitaro;
    • Komatsu, Kanji;
    • Morita, Satoshi;
    • Fukuoka, Masahiro;
    • Nakagawa, Kazuhiko
    Publication type:
    Article
    27
    28

    Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.

    Published in:
    Cancer Science, 2014, v. 105, n. 12, p. 1584, doi. 10.1111/cas.12550
    By:
    • Gemma, Akihiko;
    • Kudoh, Shoji;
    • Ando, Masahiko;
    • Ohe, Yuichiro;
    • Nakagawa, Kazuhiko;
    • Johkoh, Takeshi;
    • Yamazaki, Naoya;
    • Arakawa, Hiroaki;
    • Inoue, Yoshikazu;
    • Ebina, Masahito;
    • Kusumoto, Masahiko;
    • Kuwano, Kazuyoshi;
    • Sakai, Fumikazu;
    • Taniguchi, Hiroyuki;
    • Fukuda, Yuh;
    • Seki, Akihiro;
    • Ishii, Tadashi;
    • Fukuoka, Masahiro
    Publication type:
    Article
    29
    30
    31
    32
    33

    Curcumin prevents and reverses murine cardiac hypertrophy.

    Published in:
    2008
    By:
    • Li, Hong-Liang;
    • Liu, Chen;
    • de Couto, Geoffrey;
    • Ouzounian, Maral;
    • Sun, Mei;
    • Wang, Ai-Bing;
    • Huang, Yue;
    • He, Cheng-Wei;
    • Shi, Yu;
    • Chen, Xin;
    • Nghiem, Mai P;
    • Liu, Youan;
    • Chen, Manyin;
    • Dawood, Fayez;
    • Fukuoka, Masahiro;
    • Maekawa, Yuichiro;
    • Zhang, Liyong;
    • Leask, Andrew;
    • Ghosh, Asish K;
    • Kirshenbaum, Lorrie A
    Publication type:
    journal article
    34

    Curcumin prevents and reverses murine cardiac hypertrophy.

    Published in:
    Journal of Clinical Investigation, 2008, v. 118, n. 3, p. 879
    By:
    • Hong-Liang Li;
    • Chen Liu;
    • de Couto, Geoffrey;
    • Ouzounian, Maral;
    • Mei Sun;
    • Ai-Bing Wang;
    • Yue Huang;
    • Cheng-Wei He;
    • Yu Shi;
    • Xin Chen;
    • Nghiem, Mai P.;
    • Youan Liu;
    • Manyin Chen;
    • Dawood, Fayez;
    • Fukuoka, Masahiro;
    • Maekawa, Yuichiro;
    • Liyong Zhang;
    • Leask, Andrew;
    • Ghosh, Asish K.;
    • Kirshenbaum, Lorrie A.
    Publication type:
    Article
    35
    36
    37
    38

    Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2007, v. 60, n. 2, p. 285, doi. 10.1007/s00280-006-0382-7
    By:
    • Tamura, Kenji;
    • Nakagawa, Kazuhiko;
    • Kurata, Takayasu;
    • Satoh, Taroh;
    • Nogami, Toshiji;
    • Takeda, Koji;
    • Mitsuoka, Shigeki;
    • Yoshimura, Naruo;
    • Kudoh, Shinzoh;
    • Negoro, Shunichi;
    • Fukuoka, Masahiro
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49

    Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB–IIIA non-small cell lung cancer (WJTOG0101).

    Published in:
    International Journal of Clinical Oncology, 2021, v. 26, n. 12, p. 2216, doi. 10.1007/s10147-021-02012-9
    By:
    • Yamaguchi, Masafumi;
    • Tada, Hirohito;
    • Mitsudomi, Tetsuya;
    • Seto, Takashi;
    • Yokoi, Kohei;
    • Katakami, Nobuyuki;
    • Nakagawa, Kazuhiko;
    • Oda, Makoto;
    • Ohta, Mitsunori;
    • Sawa, Toshiyuki;
    • Yamashita, Motohiro;
    • Iked, Norihiko;
    • Saka, Hideo;
    • Higashiyama, Masahiko;
    • Nomori, Hiroaki;
    • Semba, Hiroshi;
    • Negoro, Shunichi;
    • Chiba, Yasutaka;
    • Shimokawa, Mototsugu;
    • Fukuoka, Masahiro
    Publication type:
    Article
    50